ArticleCurrent gene therapy2015
Controlled gene delivery can enhance therapeutic outcome for cancer immune therapy for melanoma.
Article in Current gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Intratumor delivery of a novel plasmid combination induces high levels of metastatic melanoma regression.Gene therapy · 2026Article
- Effective gene immunotherapy for melanoma utilizing an advancedMolecular therapy. Oncology · 2025Article
- IL-12 and PD-1 peptide combination gene therapy for the treatment of melanoma.Molecular therapy. Nucleic acids · 2024Article
- Editorial: Pulsed electric field based technologies for oncology applications.Frontiers in oncology · 2023Article
- The effectiveness of calcium electroporation combined with gene electrotransfer of a plasmid encoding IL-12 is tumor type-dependent.Frontiers in immunology · 2023Article
- Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma.Pharmaceutics · 2022Article
- Review
- Tumor perfusion evaluation using dynamic contrast-enhanced ultrasound after electrochemotherapy and IL-12 plasmid electrotransfer in murine melanoma.Scientific reports · 2021Article
- Article
- The Efficiency of Gene Electrotransfer in Breast-Cancer Cell Lines Cultured on a Novel Collagen-Free 3D Scaffold.Cancers · 2020Article
- Article
- Immunology of IL-12: An update on functional activities and implications for disease.EXCLI journal · 2020Review
- A Novel Method for Controlled Gene Expression via Combined Bleomycin and Plasmid DNA Electrotransfer.International journal of molecular sciences · 2019Article
- Pre-clinical investigation of the synergy effect of interleukin-12 gene-electro-transfer during partially irreversible electropermeabilization against melanoma.Journal for immunotherapy of cancer · 2019Article
- Article
- Antitumor effect of antibiotic resistance gene-free plasmids encoding interleukin-12 in canine melanoma model.Cancer gene therapy · 2018Article
- Tumor cell death after electrotransfer of plasmid DNA is associated with cytosolic DNA sensor upregulation.Oncotarget · 2018Article
- Electrotransfer of Different Control Plasmids Elicits Different Antitumor Effectiveness in B16.F10 Melanoma.Cancers · 2018Article
- Gene Electrotransfer of Plasmid-Encoding IL-12 Recruits the M1 Macrophages and Antigen-Presenting Cells Inducing the Eradication of Aggressive B16F10 Murine Melanoma.Mediators of inflammation · 2017Article
- Electrotransfer parameters as a tool for controlled and targeted gene expression in skin.Molecular therapy. Nucleic acids · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Effective delivery still remains a major hurdle in the development of gene based therapies. While technological advances have occurred that have improved delivery in general, there is still a need for controlled delivery in order to achieve therapeutic effects. Gene electrotransfer (GET) can be utilized to accomplish this. Careful selection of parameters used for delivery such as amplitude, duration and number of pulses as well as plasmid construct can be manipulated in order to achieve appropriate levels of local expression. Previously we have shown that direct delivery of the therapeutic cytokine, interleukin 12 (IL-12), to tumors using electrotransfer can generate local and systemic anti-tumor effects in pre-clinical and clinical studies. Using this model we hypothesized that modulating local gene expression using GET can affect therapeutic outcome. To test this, we used multiple GET protocols and plasmids to achieve varying levels of local IL-12 expression. We found that high local gene expression did not give rise to a better therapeutic outcome. This suggests the level and possibly the duration of gene expression are important in mediating the host immune response against melanoma. These data also emphasize the importance of considering the desired immune outcome of the therapy when selecting parameters for GET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.